J Peter Van Tintelen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9026568/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace, 2022, 24, 285-295.	0.7	7
2	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace, 2022, 24, 296-305.	0.7	9
3	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. Heart Rhythm, 2022, 19, 427-434.	0.3	8
4	A tailored approach to informing relatives at risk of inherited cardiac conditions: results of a randomised controlled trial. European Journal of Human Genetics, 2022, 30, 203-210.	1.4	7
5	Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010221.	2.1	5
6	Echocardiographic Deformation ImagingÂfor Early Detection of GeneticÂCardiomyopathies. Journal of the American College of Cardiology, 2022, 79, 594-608.	1.2	10
7	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic RightÂVentricular Cardiomyopathy. JACC: Clinical Electrophysiology, 2022, 8, 306-318.	1.3	10
8	Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Research, 2022, 60, 102737.	0.3	3
9	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2022, 19, 1659-1665.	0.3	6
10	Genetic Basis of Dilated Cardiomyopathy in Dogs and Its Potential as a Bidirectional Model. Animals, 2022, 12, 1679.	1.0	5
11	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
12	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	1.6	21
13	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213
14	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction. European Heart Journal, 2021, 42, 2842-2850.	1.0	54
15	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circulation Genomic and Precision Medicine, 2021, 14, e003273.	1.6	112
16	The genetic architecture of Plakophilin 2 cardiomyopathy. Genetics in Medicine, 2021, 23, 1961-1968.	1.1	13
17	Terminal osseous dysplasia with pigmentary defects and cardiomyopathy caused by a novel FLNA variant. American Journal of Medical Genetics, Part A, 2021, 185, 3814-3820.	0.7	1
18	Epicardial differentiation drives fibro-fatty remodeling in arrhythmogenic cardiomyopathy. Science Translational Medicine, 2021, 13, eabf2750.	5.8	16

#	Article	IF	CITATIONS
19	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
20	Uptake and Patient Perspectives on Additional Testing for Novel Disease-Associated Genes: Lessons from a PAH Cohort. Genes, 2021, 12, 1540.	1.0	1
21	Global approaches to cardiogenetic evaluation after sudden cardiac death in the young: A survey among health care professionals. Heart Rhythm, 2021, 18, 1637-1644.	0.3	8
22	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
23	Phenotypic spectrum of <i>TGFB3</i> diseaseâ€causing variants in a Dutchâ€French cohort and first report of a homozygous patient. Clinical Genetics, 2020, 97, 723-730.	1.0	15
24	Genetic Evaluation in a Cohort of 126 Dutch Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1191.	1.0	12
25	Desmin is essential for the structure and function of the sinoatrial node: implications for increased arrhythmogenesis. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H557-H570.	1.5	11
26	Prevalence and Prognostic Impact of Pathogenic Variants in Patients With Dilated Cardiomyopathy Referred for Ventricular Tachycardia Ablation. JACC: Clinical Electrophysiology, 2020, 6, 1103-1114.	1.3	16
27	Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circulation Genomic and Precision Medicine, 2020, 13, 548-550.	1.6	4
28	Long-Term Follow-Up Study on the Uptake of Genetic Counseling and Predictive DNA Testing in Inherited Cardiac Conditions. Circulation Genomic and Precision Medicine, 2020, 13, 524-530.	1.6	11
29	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
30	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	1.6	38
31	Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants. Journal of Clinical Medicine, 2020, 9, 545.	1.0	12
32	The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. European Heart Journal, 2020, 41, 1393-1400.	1.0	54
33	Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5. Heart Rhythm, 2020, 17, 945-954.	0.3	28
34	Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathy. Journal of Medical Genetics, 2020, 57, 23-30.	1.5	16
35	Diagnosing arrhythmogenic right ventricular cardiomyopathy by 2010 Task Force Criteria: clinical performance and simplified practical implementation. Europace, 2020, 22, 787-796.	0.7	40
36	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	0.9	17

#	Article	IF	CITATIONS
37	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
38	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circulation Genomic and Precision Medicine, 2019, 12, e002467.	1.6	38
39	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circulation Genomic and Precision Medicine, 2019, 12, e002460.	1.6	267
40	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	2.9	84
41	Fetal methotrexate syndrome: A systematic review of case reports. Reproductive Toxicology, 2019, 87, 125-139.	1.3	33
42	Mortality Risk Associated With Truncating Founder Mutations in Titin. Circulation Genomic and Precision Medicine, 2019, 12, e002436.	1.6	5
43	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
44	Informing relatives at risk of inherited cardiac conditions: experiences and attitudes of healthcare professionals and counselees. European Journal of Human Genetics, 2019, 27, 1341-1350.	1.4	10
45	Relevance of Titin Missense and Non-Frameshifting Insertions/Deletions Variants in Dilated Cardiomyopathy. Scientific Reports, 2019, 9, 4093.	1.6	30
46	A tailored approach towards informing relatives at risk of inherited cardiac conditions: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e025660.	0.8	2
47	Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovascular Pathology, 2019, 40, 2-6.	0.7	16
48	Flotillins in the intercalated disc are potential modulators of cardiac excitability. Journal of Molecular and Cellular Cardiology, 2019, 126, 86-95.	0.9	3
49	Autosomal dominant Marfan syndrome caused by a previously reported recessive <i>FBN1</i> variant. Molecular Genetics & Genomic Medicine, 2019, 7, e00518.	0.6	6
50	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	0.5	48
51	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
52	Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genetics in Medicine, 2018, 20, 1374-1386.	1.1	36
53	Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm, 2018, 15, 1097-1107.	0.3	79
54	Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension Syndrome. Circulation Research, 2018, 122, 846-854.	2.0	22

#	Article	IF	CITATIONS
55	Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genetics in Medicine, 2018, 20, 351-359.	1.1	283
56	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. European Heart Journal, 2018, 39, 2898-2907.	1.0	17
57	Cardiac Arrest During Spine Surgery in the Prone Position: Case Report and Review of the Literature. World Neurosurgery, 2018, 115, 460-467.e1.	0.7	6
58	ldentification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	0.8	15
59	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. Circulation Genomic and Precision Medicine, 2018, 11, e001797.	1.6	10
60	Desmoplakin Gene Variants and Risk for Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002241.	1.6	11
61	Whole-Exome Sequencing Identifies Pathogenic Variants in <i>TJP1</i> Gene Associated With Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002123.	1.6	38
62	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2
63	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	1.8	148
64	Isolated Subepicardial Right Ventricular Outflow Tract Scar in Athletes With VentricularÂTachycardia. Journal of the American College of Cardiology, 2017, 69, 497-507.	1.2	56
65	Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison. European Journal of Human Genetics, 2017, 25, 169-175.	1.4	8
66	Burden of Recurrent and Ancestral Mutations in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
67	Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Failure Reviews, 2017, 22, 263-277.	1.7	18
68	Large Genomic Rearrangements of Desmosomal Genes in Italian Arrhythmogenic Cardiomyopathy Patients. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	35
69	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovascular Research, 2017, 113, 1521-1531.	1.8	98
70	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. Cardiovascular Pathology, 2017, 30, 23-26.	0.7	17
71	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. European Journal of Heart Failure, 2017, 19, 512-521.	2.9	127
72	High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation. PLoS ONE, 2017, 12, e0189489.	1.1	33

#	Article	IF	CITATIONS
73	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	1.2	50
74	Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology, 2016, 69, 542-550.	1.6	46
75	QRS prolongation after premature stimulation is associated with polymorphic ventricular tachycardia in nonischemic cardiomyopathy: Results from the Leiden Nonischemic Cardiomyopathy Study. Heart Rhythm, 2016, 13, 860-869.	0.3	7
76	Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 515-525.	1.2	70
77	Hypertrophic remodelling in cardiac regulatory myosin light chain (<i>MYL2</i>) founder mutation carriers. European Heart Journal, 2016, 37, 1815-1822.	1.0	63
78	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. European Heart Journal, 2016, 37, 755-763.	1.0	68
79	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the PediatricÂPopulation. JACC: Clinical Electrophysiology, 2015, 1, 551-560.	1.3	74
80	The ARVD/C Genetic Variants Database: 2014 Update. Human Mutation, 2015, 36, 403-410.	1.1	77
81	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	1.0	338
82	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal, 2015, 36, 1367-1370.	1.0	75
83	Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy. Basic Research in Cardiology, 2015, 110, 27.	2.5	38
84	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation: Cardiovascular Genetics, 2015, 8, 437-446.	5.1	370
85	A group approach to genetic counselling of cardiomyopathy patients: satisfaction and psychological outcomes sufficient for further implementation. European Journal of Human Genetics, 2015, 23, 1462-1467.	1.4	14
86	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. European Heart Journal, 2015, 36, 872-881.	1.0	56
87	Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). European Journal of Human Genetics, 2014, 22, 293-293.	1.4	27
88	Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart, 2014, 1, e000116.	0.9	40
89	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	1.0	159
90	Functional assessment of potential splice site variants in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2014, 11, 2010-2017.	0.3	13

#	Article	IF	CITATIONS
91	Pregnancy, cardiomyopathies, and genetics. Cardiovascular Research, 2014, 101, 571-578.	1.8	40
92	Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. International Journal of Cardiology, 2014, 171, 90-92.	0.8	20
93	Outcome in Phospholamban R14del Carriers. Circulation: Cardiovascular Genetics, 2014, 7, 455-465.	5.1	146
94	Clinical utility gene card for: Dilated Cardiomyopathy (CMD). European Journal of Human Genetics, 2013, 21, 1185-1185.	1.4	30
95	Mortality of Inherited Arrhythmia Syndromes. Circulation: Cardiovascular Genetics, 2012, 5, 183-189.	5.1	39
96	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	2.9	369
97	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2011, 123, 2690-2700.	1.6	194
98	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Diagnostic Task Force Criteria. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 126-133.	2.1	65
99	Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm, 2010, 7, 1058-1064.	0.3	97
100	Family letters are an effective way to inform relatives about inherited cardiac disease. American Journal of Medical Genetics, Part A, 2009, 149A, 357-363.	0.7	77
101	Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm, 2009, 6, 1574-1583.	0.3	143
102	Activation Delay and VT Parameters in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Toward Improvement of Diagnostic ECG Criteria. Journal of Cardiovascular Electrophysiology, 2008, 19, 775-781.	0.8	102
103	Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon?. Current Opinion in Cardiology, 2007, 22, 185-192.	0.8	67
104	High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. American Heart Journal, 2007, 154, 1130-1139.	1.2	150
105	Severe Myocardial Fibrosis Caused by a Deletion of the 5' End of the Lamin A/C Gene. Journal of the American College of Cardiology, 2007, 49, 2430-2439.	1.2	79
106	Plakophilin-2 Mutations Are the Major Determinant of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2006, 113, 1650-1658.	1.6	326